Radioiodide (131I) therapy for the treatment of canine thyroid carcinoma

被引:48
|
作者
Worth, AJ
Zuber, RM
Hocking, M
机构
[1] Massey Univ, Vet Teaching Hosp, Ctr Compan Anim Hlth, Palmerston North, New Zealand
[2] Gladesville Vet Hosp, Gladesville, NSW 2111, Australia
关键词
D O I
10.1111/j.1751-0813.2005.tb11650.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective To assess the efficacy of radioactive iodine treatment (I-131) for canine thyroid carcinoma, as both the sole therapeutic modality and as an adjunct to surgery. Design Retrospective analysis of case records from the Gladesville Veterinary Hospital Nuclear Medicine Service, Sydney, between August 1988 and December 2001. Case Details The records of 65 dogs with thyroid carcinoma were analysed according to therapy and outcome. Forty-three dogs received radioiodide therapy, either as the sole therapeutic modality (32) or as an adjunct to surgery (11). Radioisotope therapy consisted of one to three doses of I-131 with a dose range of 555 to 1850 MBq. For analysis, dogs were divided into groups according to therapy: no treatment, surgery alone, surgery with radioiodide therapy or radioiodide therapy alone. Mode of therapy, dosage of I-131, clinical staging and age were all independently analysed according to survival to compare efficacy or predictive value respectively. Results When radioiodide therapy was used as an adjunct to surgery, median survival was 34 months. Censored median survival time for dogs that received radioiodide alone was 30 months. Dogs that did not receive treatment had a median survival of only 3 months. Log rank statistical analysis indicated that mode of therapy was significantly correlated with survival but that clinical stage of disease was not. Conclusion The authors conclude that I-131 therapy is effective at extending survival time, both as a sole therapeutic modality and as an adjunct to surgery, in dogs with invasive canine thyroid carcinoma. Incomplete surgical resection may not prolong survival in dogs also receiving I-131 therapy, however surgical resection with curative intent should be recommended as the first line of therapy for mobile thyroid carcinomas. Radioisotope therapy can be recommended for cases where surgery alone is considered unlikely to be curative because of metastatic disease or local invasion, or for cases where surgery has been attempted but complete surgical removal has not been achieved.
引用
收藏
页码:208 / 214
页数:7
相关论文
共 50 条
  • [21] Thyroid Cancer Therapy with 131I: A Comprehensive Review
    Rodriguez-Santiago, Stephanie
    Cantu, Ernesto
    Wagner, Robert
    Savir-Baruch, Bital
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [22] Gut microbiota is associated with response to 131I therapy in patients with papillary thyroid carcinoma
    Zheng, Lei
    Zhang, Linjing
    Tang, Li
    Huang, Dingde
    Pan, Deng
    Guo, Wei
    He, Song
    Huang, Yong
    Chen, Yu
    Xiao, Xu
    Tang, Bo
    Chen, Jing
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (05) : 1453 - 1465
  • [23] Gut microbiota is associated with response to 131I therapy in patients with papillary thyroid carcinoma
    Lei Zheng
    Linjing Zhang
    Li Tang
    Dingde Huang
    Deng Pan
    Wei Guo
    Song He
    Yong Huang
    Yu Chen
    Xu Xiao
    Bo Tang
    Jing Chen
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 1453 - 1465
  • [24] Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma
    Koong, SS
    Reynolds, JC
    Movius, EG
    Keenan, AM
    Ain, KB
    Lakshmanan, MC
    Robbins, J
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (03): : 912 - 916
  • [25] Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma
    Grigsby, PW
    Siegel, BA
    Baker, S
    Eichling, JO
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (17): : 2272 - 2274
  • [26] Bone Marrow Function After 131I Therapy in Patients With Differentiated Thyroid Carcinoma
    Prinsen, Hester T.
    Hesselink, Esther N. Klein
    Brouwers, Adrienne H.
    Plukker, John T. M.
    Sluiter, Wim J.
    van der Horst-Schrivers, Anouk N. A.
    van Imhoff, Gustaaf W.
    Links, Thera P.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (10): : 3911 - 3917
  • [27] Treatment effect of higher cumulativedose of 131I therapy for differentiated thyroid carcinoma h diffuse pulmonary metastases
    Li, Fei
    Zhang, Jing
    Wu, Yuping
    Liu, Jianzhong
    Wu, Zhifang
    Li, Sijin
    Lu, Keyi
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [28] THYROID ANTIBODIES AFTER 131I TREATMENT FOR HYPERTHYROIDISM
    EINHORN, J
    FAGRAEUS, A
    JONSSON, J
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1965, 25 (09): : 1218 - +
  • [29] Hospital discharge of patients with thyroid carcinoma treated with 131I
    Venencia, CD
    Germanier, AG
    Bustos, SR
    Giovannini, AA
    Wyse, EP
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (01) : 61 - 65
  • [30] 131I Radiation Dose Distribution in Metastases of Thyroid Carcinoma
    Eterovic, Davor
    Markovic, Vinko
    Punda, Ante
    Antunovic, Zeljko
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (05) : 833 - 834